

Letter to the Editor

Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: The NIH experience

To the Editor:

Although the efficacy of granulocyte transfusion(s) (GT) has not been definitively proven, they are used as an adjunctive therapy to antimicrobials in the treatment of patients with severe or treatment-refractory infections in the setting of neutropenia or granulocyte dysfunction, as in chronic granulomatous disease (CGD).¹⁻⁴ Despite new and improved antimicrobial prophylactic and therapeutic measures, severe infections continue to be life-threatening and the main cause of death in patients with CGD.⁵

We retrospectively reviewed the medical records of patients with CGD with severe and refractory infections who received GT at the National Institutes of Health (NIH) Clinical Center, from 1984 to 2012. All patients had CGD confirmed by molecular, immunoblot, and/or nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase functional assays; all consented to NIH research protocols. Patients' demographic characteristics were analyzed on the basis of sex, CGD genotype, and age at GT use. Infections were classified on the basis of (a) affected site; (b) extent (localized vs disseminated), and (c) microbiology.

GT data were analyzed on the basis of total number of transfusions per cycle, the periodicity of transfusions, and the median number of granulocytes/kg/transfusion. Each GT cycle was considered an independent course aiming to treat a particular infection. Adverse events (AEs) associated with GT were also analyzed. All patients were treated with antimicrobials before, during, and after the GT on the basis of organism speciation and sensitivity. Debulking surgery to remove infected tissue was performed before, during, and after GT as clinically indicated. GT was used in patients when medical and/or surgical treatments failed to control underlying infections.

GT treatment initiation was categorized as early (≤ 1 month) or delayed (> 1 month) after infectious disease clinical/microbiologic diagnosis. Infection outcome/efficacy following GT was categorized as cleared (CL), partially cleared (pCL), or not cleared (nCL). An infection was considered CL after GT when complete clinical and microbiologic resolution was achieved. A pCL infection was defined as overall clinical and/or microbiologic improvement in the patient's status. An nCL infection was defined as clinical and/or microbiologic progression following GT, or if the patient died from the infection. Categorical variables were presented as totals and percentages. Continuous variables were summarized by median and range. Statistical analysis of all continuous variables was carried out using the Mann-Whitney test, and all categorical variables that potentially impacted outcome were analyzed using chi-square or Fisher exact test depending on sample size. All reported *P* values are 2-sided using a level of significance of .05. Data analyses were generated using PRISM 6 for MAC OSX.

Sixty-nine GT courses aiming to treat an equal number of refractory infections were used in 48 patients with CGD over a 29-year period at the NIH (NIH CGD cohort, *n* = 234). GTs in the context of hematopoietic stem cell transplantation (HSCT; *n* = 7) were excluded from all analysis; GTs associated with early onset

AEs precluding further transfusions (*n* = 4, 6.5% of 62 GT courses initiated; range, 2-6 total transfusions in 2-11 days) were excluded from efficacy analysis. Finally, 58 GT courses in 40 patients with CGD (22 X-linked [*CYBB*/gp91^{phox}], 17 autosomal-recessive [14, *NCF1*/p47; 2, *CYBA*/p22^{phox}; and 1, *NCF3*/p67^{phox}], and 1 extremely lyonized X-linked CGD female carrier) were analyzed. Eight patients with CGD received multiple GT courses (range, 2-6) to treat different infections. Nine females and 31 males were treated. Microbiology was definitive in 51 of 58 infections reviewed (88%), the majority fungal. Debulking surgery (resection or debridement) was performed in 16 cases (30%), either during or immediately after the GT course. GTs were associated with CL (*n* = 42) or pCL infections (*n* = 9) in 51 of 58 (88%) episodes. Of the 7 nCL infections, 6 (1 bacterial, 4 fungal, and 1 polymicrobial) caused the patient's demise. Two of these patients had previous infections CL after GT. GT therapy was more frequently used before 2002 (51 courses, average 2.8/y) than thereafter (7 courses, average 0.7/y). GT showed an overall efficacy of 88% for CL + pCL infections; 94% before 2002, which decreased to 43% since then.

To examine efficacy, the 58 GT-treated infectious episodes were stratified into those that improved after GT therapy (CL + pCL) versus those that did not (nCL) (Table 1). The overall success rate associated with GT in microbiologically confirmed infections was not significantly different between fungal (82%) and bacterial (94%) infections. The efficacy of adjunctive GT therapy was independent of CGD genotype: 87% of infections CL + pCL in patients with X-linked CGD, as did 88% of infections in patients with autosomal-recessive disease (*P* = 1). When we compared patients who CL + pCL versus nCL their infections, the first group received significantly more (≥ 25 vs 15 transfusions) and more frequent transfusions ($\leq$ every 2 days vs $>$ every 2 days). Despite changes in methods for granulocyte collection (dexamethasone alone until 1995, dexamethasone and granulocyte-colony stimulating factor thereafter), all patients received high-dose GT (median, $\geq 0.6 \times 10^9$ granulocytes/kg/transfusion) and no significant differences were detected between groups. Patients who had CL + pCL were younger than those who had nCL infections (median, 14 vs 30 years). Patients starting early GT therapy were significantly more likely to have CL + pCL infections than those in whom GT initiation was delayed (≤ 1 month vs > 1 month).

A total of 1594 individual GTs were used on the 58 GT courses analyzed. AEs were reported in 31 of the 1594 individual transfusions (2%), affecting 12 patients (29%), none of them lethal. All recorded AEs included fever and/or chills either alone or associated with rigors, flushing, vomiting, irritability, or agitation. Two patients developed transient dyspnea, one of whom was reported as transfusion-related acute lung injury. Thirteen patients developed anti-HLA antibodies, 6 of whom also showed anti-RBC antibodies. Three other patients developed only anti-RBC antibodies. As mentioned above, GTs were stopped after 4 AEs, 2 of them occurring in the same patient while treating different infections.

Our single-center retrospective study of GT as an adjunctive therapy in patients with CGD with refractory infections showed that overall more than 80% of the infections improved with this approach. GTs were more often associated with favorable

TABLE I. GTs in patients with CGD, characteristics

GT characteristics n = 58	Improved n = 51		Not improved n = 7		Efficacy/significance
	CL n = 42	pCL n = 9	nCL n = 7*	CL + pCL vs nCL	
Age at GT (y)†	16 (2-63)	14 (2-38)	16 (5-30)	30 (12-63)	0.003
Number of GTs†	27 (2-150)	29 (2-150)	25 (6-63)	15 (4-27)	0.01
Administration period (d)†	48 (2-287)	50 (2-287)	50 (9-168)	37 (7-72)	0.3
Frequency (d)†	1.8 (1-8.5)	1.7 (1-8.5)	1.8 (1.1-4.6)	2.2 (1.2-3)	0.01
Median number of granulocytes/kg	0.92×10^9	0.84×10^9	1.09×10^9	0.97×10^9	0.59
Early/delayed GT initiation	32/26	26/16	5/4	1/6	0.03
Type of infection					
Localized	40 (69%)	30	7	3	0.18
Disseminated	18 (31%)	12	2	4	
Lung	37 (64%)	29	4	4	
Liver	15 (26%)	9	4	2	
Central nervous system	2 (3%)	2	0	0	0.63
Bones	2 (3%)	2	0	0	
Lymph nodes	2 (3%)	1	0	1	
Fungal	28 (48%)	19	4	5	
Bacterial	19 (33%)	15	3	1	0.37
Polymicrobial	4 (7%)	2	1	1	
No isolate	7 (12%)	6	1	0	

Statistically significant values are in boldface.

*Out of the 7 patients who did not clear their infections after GT, 6 died. The cause of death was bacterial in 1 (*Burkholderia pseudomallei*), fungal in 4 (*Paecilomyces variotii* in 1, *Aspergillus tanneri* in 1, *Phaeoacremonium parasiticum* in 1, and *Aspergillus fumigatus* in 1), and polymicrobial in 1 (*Staphylococcus aureus* + *Aspergillus flavus* + *Rhizopus microsporus* + *Paecilomyces variotii*); the seventh patient (infected with *Mucor* spp.) improved after further antifungal and surgical treatment. None of these patients experienced AE to GT.

†Mean (range).

outcomes when transfusions were implemented early in the course of illness and when the number of infusions was higher. These results were independent of the CGD genotype, whether fungi or bacteria caused the infection, the site of infection, or whether it was localized or disseminated.

Since 2002 the overall use of GT declined in our center. Multiple variables have likely influenced this change in practice, including increased use of HSCT as a curative approach. HSCT has also been used to successfully treat severe infections in CGD not responding to conventional therapy.⁶ In addition, with the increased use of HSCT, there has been avoidance of GT due to the attendant risk of HLA allosensitization, a major complication for HSCT.⁷ Finally, the availability of more effective antibacterials and antifungals⁸ may have led to fewer severe/refractory infections requiring GT. Therefore, with the confounding changes in practice and treatment, it is difficult to compare the intervals of GT use.

Whether the use of GT is causally associated with better outcomes or simply a marker for better survival cannot be determined on the basis of the retrospective nature of this study and the intrinsic limitations of the analysis performed. It is formally possible that those patients who better tolerated GT and who were able to receive more infusions were less sick at the outset and who had slow but successful responses to other antimicrobial therapies. The association of better outcomes with younger age may correlate with less underlying end-organ damage, and reflect the overall low mortality in childhood.⁹ However, our data suggest that GT is relatively safe with few significant complications.

This is the largest cohort of patients with CGD treated with GT. Based on previous selected cases, there was insufficient evidence to support the routine use of GT in the treatment of refractory

infections in CGD. Our single-center experience suggests, although does not formally prove, that timely, frequent, and sustained GT is relatively safe and associated with better outcomes. Alloimmunization remains a concern for those patients anticipating HSCT.⁷

The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.

Beatriz E. Marciano, MD^a
 Elisabeth S. Allen, MD^b
 Cathy Conry-Cantilena, MD^b
 Ervand Kristosturyan, MD^a
 Harvey G. Klein, MD^b
 Thomas A. Fleisher, MD^c
 Steven M. Holland, MD^a
 Harry L. Malech, MD^d
 Sergio D. Rosenzweig, MD, PhD^{c,e}

From ^athe Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), ^bthe Department of Transfusion Medicine, NIH Clinical Center, ^cthe Immunology Service, Department of Laboratory Medicine, NIH Clinical Center, ^dthe Laboratory of Host Defenses, NIAID, and ^ethe Primary Immunodeficiency Clinic, NIAID, National Institutes of Health, Bethesda, Md. E-mail: srosenzweig@cc.nih.gov.

This work was supported by the Intramural Research Program of the National Institutes of Health Clinical Center and the National Institutes of Allergy and Infectious Diseases.

Disclosure of potential conflict of interest: T. A. Fleisher was president of the American Academy of Allergy, Asthma & Immunology; has received payment for lectures from the Boston City Wide Allergy Meeting, the Louisiana Society of Allergy, Asthma, and Immunology, and the Alaska Society of Allergy, Asthma, and Immunology; and has received royalties as co-editor of *Clinical Immunology: Principles and Practice*. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

1. Yoshihara S, Ikemoto J, Fujimori Y. Update on granulocyte transfusions: accumulation of promising data, but still lack of decisive evidence. *Curr Opin Hematol* 2016;23:55-60.
2. Stanworth SJ, Massey E, Hyde C, Brunskill S, Lucas G, Navarrete C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. *Cochrane Database Syst Rev* 2005;(3):CD005339.
3. Ikinciogullari A, Dogu F, Solaz N, Reisli I, Kemahli S, Cin S, et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. *Ther Apher Dial* 2005;9:137-41.
4. Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, Strauss RG, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. *Blood* 2015;126:2153-61.
5. Holland SM. Chronic granulomatous disease. *Hematol Oncol Clin North Am* 2013;27:89-99, viii.
6. Parta M, Hilligoss D, Kelly C, Kwatemaa N, Theobald N, Malech H, et al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. *J Clin Immunol* 2015;35:675-80.
7. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, Leitman SF. Alloimmunization after granulocyte transfusions. *Transfusion* 1996;36:1009-15.
8. Allen D, Wilson D, Drew R, Perfect J. Azole antifungals: 35 years of invasive fungal infection management. *Expert Rev Anti Infect Ther* 2015;13:787-98.
9. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. *N Engl J Med* 2010;363:2600-10.

<http://dx.doi.org/10.1016/j.jaci.2017.02.026>